ASX Runners of the Week: Killi, Amplia, NuEnergy and 4D Medical

Why It Matters

These catalysts highlight how board upgrades, breakthrough clinical data, energy‑security bets, and high‑profile medical endorsements can rapidly reshape investor sentiment across diverse ASX sectors.

Key Takeaways

• Killi appoints Nev Power, raises $1.4M, secures Queensland grant.
• Amplia reports 7.8% complete response in pancreatic trial.
• NuEnergy's coal‑bed methane project targets Indonesian gas scarcity.
• 4D Medical's CT:VQ adopted by Mayo Clinic, boosting credibility.
• All four stocks surged, driven by strong catalyst announcements.

Pulse Analysis

The ASX’s junior‑miner segment is once again proving sensitive to high‑profile governance changes and government‑backed exploration funding. Killi Resources’ board overhaul, featuring Nev Power—a figure synonymous with scaling resource giants—has not only attracted capital but also unlocked a Queensland Collaborative Exploration Initiative grant. Such endorsements signal to investors that the company possesses both strategic leadership and tangible drilling upside, a rare combination that can accelerate valuation in early‑stage mining ventures.

Biotech investors are closely watching Amplia Therapeutics as its ACCENT trial delivers an unprecedented five complete responses out of 64 patients, a 7.8% rate that far exceeds historical benchmarks for metastatic pancreatic cancer. Coupled with an FDA registration, the data positions Amplia to capture a sizable share of a market plagued by low survival rates and limited therapeutic options. The company’s rapid price appreciation underscores the premium investors place on clinical breakthroughs that promise both commercial licensing revenue and potential partnership opportunities with global pharma players.

Energy scarcity and medical‑technology adoption are converging to create new speculative narratives on the ASX. NuEnergy Gas, despite a lack of fresh operational updates, has seen its share price double as market participants bet on Indonesia’s first commercial‑scale coal‑bed methane project to fill looming gas supply gaps. Simultaneously, 4D Medical’s CT:VQ platform gaining traction at the Mayo Clinic—a leading U.S. health institution—offers a cost‑effective, non‑radioactive alternative to traditional ventilation‑perfusion scans. Both stories illustrate how strategic positioning in emerging supply‑chain bottlenecks and validated clinical tools can drive outsized investor interest, reinforcing the importance of catalyst‑driven momentum in small‑cap Australian equities.